Ready for a rapid, radical reboot of the global innovation system for a truly free and open 21st century knowledge economy?
The Open Science Summit is an attempt to gather all stakeholders who want to liberate our scientific and technological commons and enable a new era of decentralized, distributed innovation to solve humanity's greatest challenges.
Bio
Barry Bunin
Barry A. Bunin, Ph.D. is the CEO of Collaborative Drug Discovery. Dr. Bunin has overseen over $18 million in business transactions. Prior to CDD, Dr. Bunin was an Entrepreneur in Residence with Eli Lilly & Co. Before that he was the founding CEO, President, & CSO of Libraria (now Eidogen-Sertanty). At Libraria, Dr. Bunin led a team that integrated exhaustive reaction capture (synthetic chemistry) with gene-family wide SAR capture (medicinal chemistry). On the scientific side, he co-authored Chemoinformatics: Theory, Practice, and Products (Springer-Verlag), a text that overviews modern chemoinformatics technologies, and The Combinatorial Index (Academic Press), a widely used text on high-throughput chemical synthesis. In the lab, Dr. Bunin did medicinal synthetic chemistry developing patented new chemotypes for protease inhibition at Axys Pharmaceuticals (now Celera) and RGD mimics to inhibit GP-IIbIIIa at Genentech.
Dr. Bunin received his B.A. from Columbia University and his Ph.D. from UC Berkeley, where he synthesized and tested the initial 1,4-benzodiazepine libraries with Professor Jonathan Ellman.
Andrew Hessel
Andrew Hessel is the founder and managing director of the Pink Army Cooperative. After earning degrees in cellular biology and bacterial genomics, he joined the Amgen Institute in Toronto, where he learned firsthand the challenges of novel drug development.
A champion of open source synthetic biology since 2004, he now advises leading groups on strategies for open innovation, including open drug development. His work is enabling a new generation of researchers and entrepreneurs to address major bioengineering challenges, including renewable energy production, environmental preservation and remediation, and human disease.
Jonathan Izant
Professor Izant is the Vice President and COO of Sage Bionetworks. Prior to this he held positions as Deputy Director Global Health Operations at the Bill and Melinda Gates Foundation and Adjunct Professor at the Centre for Philanthropy and Nonprofit Studies at Queensland University of Technology.
Professor Izant has extensive Australian and international experience in academic research, pharmaceutical corporation product development, as well as public sector technology transfer including building and leading biotech spin-off companies. He has held senior positions at the Institute of Health and Biomedical Innovation, National Health and Medical Research Council Human Gene Advisory, Queensland Biotechnology Advisory Council; Head, Health & Medical Working Group, and e-Health Research Centre Advisory Committee.
Professor Izant has also held positions on the NH&MRC Development Grant Assessment Panel and New South Wales Health BioFirst Awards Committee.
member. 
